SK Bioscience Co (302440.KS) Stock Price

SK Bioscience Co Price

🇰🇷KOSDAQ·CLOSED
38,600.00KRW
Market closed
Today +/-
Today %

SK Bioscience Co (302440.KS) Stock | ISIN KR7302440003. The current SK Bioscience Co stock price is 38,600 KRW (2026). Revenue is 725.98 B KRW. Net income is -42.24 B KRW. The P/E ratio is -70.54. Market capitalization is 2.98 T KRW. SK Bioscience Co operates in the Health sector.

SK Bioscience Co stock price

Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of SK Bioscience Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how SK Bioscience Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing SK Bioscience Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

SK Bioscience Co Stock Price History
DateSK Bioscience Co Price
Access this data via the Eulerpool API

SK Bioscience Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
99.4 B KRW
26.44 B KRW
8.93 B KRW
Jan 1, 2019
183.94 B KRW
22.8 B KRW
14.68 B KRW
Jan 1, 2020
225.61 B KRW
37.71 B KRW
32.89 B KRW
Jan 1, 2021
929 B KRW
474.22 B KRW
355.14 B KRW
Jan 1, 2022
456.73 B KRW
115.01 B KRW
122.45 B KRW
Jan 1, 2023
369.51 B KRW
-11.99 B KRW
22.32 B KRW
Jan 1, 2024
267.55 B KRW
-138.43 B KRW
-53.88 B KRW
Invalid Date
651.05 B KRW
-113.24 B KRW
-37.59 B KRW
Invalid Date
725.98 B KRW
-70.15 B KRW
-42.24 B KRW
Invalid Date
781.09 B KRW
-50.7 B KRW
-28.75 B KRW
Invalid Date
569.64 B KRW
0 KRW
0 KRW

SK Bioscience Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 10, 2026, 4:07 PM
 
REVENUE (M KRW)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M KRW)
NET INCOME (M KRW)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales SK Bioscience Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue SK Bioscience Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare SK Bioscience Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares SK Bioscience Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against SK Bioscience Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

SK Bioscience Co stock margins

The SK Bioscience Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SK Bioscience Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SK Bioscience Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
50.75 %
26.59 %
8.99 %
Jan 1, 2019
42.33 %
12.39 %
7.98 %
Jan 1, 2020
42.26 %
16.71 %
14.58 %
Jan 1, 2021
61.39 %
51.05 %
38.23 %
Jan 1, 2022
52.46 %
25.18 %
26.81 %
Jan 1, 2023
38.5 %
-3.24 %
6.04 %
Jan 1, 2024
11.58 %
-51.74 %
-20.14 %
Invalid Date
11.58 %
-17.39 %
-5.77 %
Invalid Date
11.58 %
-9.66 %
-5.82 %
Invalid Date
11.58 %
-6.49 %
-3.68 %

SK Bioscience Co Stock Revenue, EBIT, Earnings per Share

The SK Bioscience Co earnings per share therefore indicates how much revenue SK Bioscience Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
1,629.56 KRW
433.38 KRW
146.44 KRW
Jan 1, 2019
3,015.38 KRW
373.72 KRW
240.61 KRW
Jan 1, 2020
3,638.89 KRW
608.23 KRW
530.48 KRW
Jan 1, 2021
12,582.62 KRW
6,422.95 KRW
4,810.09 KRW
Jan 1, 2022
5,929.85 KRW
1,493.27 KRW
1,589.84 KRW
Jan 1, 2023
4,797.92 KRW
-155.66 KRW
289.79 KRW
Jan 1, 2024
3,465.55 KRW
-1,793.12 KRW
-697.93 KRW
Invalid Date
8,433.19 KRW
-1,466.75 KRW
-486.86 KRW
Invalid Date
9,403.72 KRW
-908.7 KRW
-547.18 KRW
Invalid Date
10,117.54 KRW
-656.68 KRW
-372.41 KRW

SK Bioscience Co business model & stock analysis

SK bioscience Co., Ltd. engages in the development and distribution of bio and vaccine products. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-03-18. The firm's main products include vaccines such as SKYCellflu and Rotatech. The firm also sells infusion solutions. In addition, the Company engages in technology export business. The firm sells its products in domestic and overseas markets.

SK Bioscience Co Eulerpool Fair Value

SK Bioscience Co historical P/E ratio, EBIT multiple, and P/S ratio

SK Bioscience Co annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

SK Bioscience Co shares outstanding

The number of shares was SK Bioscience Co in 2025 — This indicates how many shares 77.201 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
61 M base_Shares
Jan 1, 2019
61 M base_Shares
Jan 1, 2020
62 M base_Shares
Jan 1, 2021
73.83 M base_Shares
Jan 1, 2022
77.02 M base_Shares
Jan 1, 2023
77.01 M base_Shares
Jan 1, 2024
77.2 M base_Shares
Invalid Date
77.2 M base_Shares
Invalid Date
77.2 M base_Shares
Invalid Date
77.2 M base_Shares
Price targets and forecasts for SK Bioscience Co are not yet available.

SK Bioscience Co Earnings Estimates

SK Bioscience Co Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/10/2024-304.31KRW42.12 BKRW2024 Q1
3/15/2024-316.6KRW48.44 BKRW2023 Q4

EESG©

Eulerpool ESG Scorecard© for the SK Bioscience Co stock

75/100
75
Environment
99
Social
52
Governance
E

Environment

20
Scope 1 - Direct Emissions5,173
Scope 2 - Indirect emissions from purchased energy13,320
Scope 3 - Indirect emissions within the value chain112,381
Total CO₂ emissions18,493
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees39
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

SK Bioscience Co shareholder structure

% Name
67.43365%
SK Chemicals Co., Ltd.
SK Chemicals Co., Ltd.
1.96828%
Klocke Holding GmbH
Klocke Holding GmbH
0.98011%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.46086%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
0.41938%
Samsung Asset Management Co., Ltd.
Samsung Asset Management Co., Ltd.
0.41491%
SK Bioscience Co., Ltd. Employees
SK Bioscience Co., Ltd. Employees
0.28666%
Mirae Asset Global Investments Co., Ltd.
Mirae Asset Global Investments Co., Ltd.
0.15568%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited
0.11255%
Handelsbanken Kapitalförvaltning AB
Handelsbanken Kapitalförvaltning AB
0.07629%
KB Asset Management Co., Ltd.
KB Asset Management Co., Ltd.
...

SK Bioscience Co Executives and Management Board

HK

Mr. Hun Kim

(57)

Director · since 2018

Compensation922 M KRW
JA

Mr. Jae Yong Ahn

(57)

President, Chief Executive Officer, Director · since 2018

Compensation703 M KRW
JH

Mr. Jae Seon Hwang

(47)

Chief Information Security Officer

JP

Mr. Jong Su Park

(54)

Chief Privacy Officer

JA

Mr. Jae Hyeon Ahn

(59)

Other Non-Executive Director

Frequently asked questions about SK Bioscience Co

All fundamentals and in-depth analysis of SK Bioscience Co

Our stock analysis for SK Bioscience Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SK Bioscience Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.